Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2009

Biokine Receives $1.2M to Develop Myeloma Treatment

Biokine Receives $1.2M to Develop Myeloma Treatment

Israeli government issues grant to Biokine for clinical trial of BKT140

  • Biokine Therapeutics begun a Phase I/IIa study of BKT140, a myeloma treatment, at Chaim Sheba Medical Center in Tel-Hasomer, Israel, after receiving a $1.2 million grant from the office of the chief scientist of the Israeli ministry of industry, trade and labor.

    The firm says that in experimental models, BKT140 promoted normal cell production in bone marrow and their entry into the blood while initiating death and removal of myeloma and leukemia cells.

    Biokine, founded in 2000 in Israel, focuses on the development of pharmaceuticals that control the activity of receptors for the chemokine CXCR4.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »